InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
March 02 2017 - 9:00AM
InvestorWire
New York, New York (NetworkNewsWire) – InMed
Pharmaceuticals, Inc. ("InMed") (CNSX: IN; OTCQB: IMLFF),
a biopharmaceutical company specializing in the research and
development of novel, cannabinoid-based drug therapies, today
announced the filing of an international Patent Cooperation Treaty
(PCT) application, an important component in providing intellectual
and commercial protection for INM-750 as a cannabinoid-based
topical therapy for Epidermolysis Bullosa Simplex (EBS).
Epidermolysis Bullosa (EB) is a group of inherited connective
tissue diseases that share a common manifestation of extremely
fragile skin that blisters or tears from friction or trauma.
Internal organs and bodily systems can also be affected by EB. It
results from a defect of anchoring between the dermis and epidermis
caused most frequently by the dysfunction or absence of certain
proteins, called keratins, in the skin. EB is an orphan disease
with no known treatment and has a significant unmet medical need.
INM-750 will be the first therapy developed for EB designed
specifically to modulate disease activity and to alleviate
symptoms.
It is well documented that cannabinoid compounds have unique
anti-inflammatory, analgesic and wound healing promoting properties
via several mechanisms, thus making them theoretically excellent
candidates for use in alleviating some of the symptoms associated
with EB. InMed's proprietary Bioinformatics Database Assessment
Tool predicted a dual approach that may prove beneficial to
patients: first, the ability of certain cannabinoids to play a role
in addressing key disease hallmarks (wound healing, infection,
pain, itch, inflammation) in all patients with EB; and second, the
ability of some cannabinoids to regulate the expression of various
keratins that might compensate for the dysfunctional keratins that
cause Epidermolysis Bullosa Simplex (EBS). EBS accounts for the
vast majority of EB patients. InMed conducted several in vitro and
in vivo assays and the results of these studies form the basis of
this PCT application.
The Patent Cooperation Treaty (PCT) is an international patent
law treaty, which provides a unified procedure for filing patent
applications to protect inventions in each of its member states.
There are 151 member countries within the PCT worldwide, so near
global patent coverage can be obtained through successful patent
prosecution in the U.S., Japan, Europe, Canada, Australia, New
Zealand, China, Brazil, Russia, India, and many other countries.
The original priority date for this filing was May 26, 2015,
therefore coverage of any underlying patent claims would extend for
20 years until 2035 in the United States, and may be subject to
patent term extensions that would enable years of additional
protection.
"This is a significant milestone achieved by our scientific
team's discovery and validation of a new cannabinoid therapy to
treat a serious disease with high unmet medical need. We are
looking forward to fully understanding the potential impact of
INM-750 in helping the EB community," said Dr. Sazzad Hossain,
Chief Scientific Officer of InMed Pharmaceuticals. "The
pre-clinical data emerging on the use of cannabinoids for EB, as
well as other disease targets in our drug development portfolio,
continue to validate our discovery approach using our
bioinformatics assessment tool. These drug/disease targeting
predictions are then followed by relatively quick, inexpensive, yet
highly informative confirmatory laboratory studies to validate the
predictions of the database. This approach is proving to be an
important means to shorten drug development timelines as well as
significantly reduce development costs."
About InMed
InMed is a pre-clinical stage biopharmaceutical company that
specializes in developing novel therapies through the research and
development into the extensive pharmacology of cannabinoids coupled
with innovative drug delivery systems. InMed's proprietary
bioinformatics database drug/disease targeting tool, cannabinoid
biosynthesis technology and drug development pipeline are the
fundamental value drivers of the Company. For more information,
visit www.inmedpharma.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication,
enhanced press release services and a full array of social
communication solutions. As a multifaceted financial news and
distribution company with an extensive team of journalists and
writers, NNW is uniquely positioned to best serve private and
public companies who need to reach a wide audience of investors,
consumers, journalists and the general public. NNW has an
ever-growing distribution network of more than 5,000 key
syndication outlets across the country. By cutting through the
overload of information in today's market, NNW brings its clients
unparalleled visibility, recognition and brand awareness. NNW is
where news, content and information converge. For more information,
visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website:
https://www.networknewswire.com/disclaimer.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com